|
Real-time Estimate
Tradegate
15:58:21 30/07/2026 BST
|
5-day change
|
1st Jan Change
|
|
59.25 EUR
|
-1.17%
|
 |
+6.39%
|
-5.29%
|
|
07-23 |
Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026
| | |
07-23 |
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026
|
CI
| |
07-23 |
Laboratorios Farmaceuticos Rovi, S.A. Maintains Earnings Guidance for 2026
|
CI
| |
07-23 |
Laboratorios Farmaceuticos Rovi S A : First half 2026 results press release
|
PU
| |
07-08 |
Laboratorios Farmaceuticos Rovi S A : ROVI and the Regional Government of Castilla-La Mancha promote a framework of collaboration to modernise healthcare services through technological innovation
|
PU
| |
05-09 |
Laboratorios Farmaceuticos Rovi, S.A., Q1 2026 Earnings Call, May 06, 2026
| | |
05-06 |
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026
|
CI
| |
05-06 |
Laboratorios Farmaceuticos Rovi, S.A. Updates Earnings Guidance for the Full Year 2026
|
CI
| |
05-06 |
Rovi Q1 net profit at 9.4 mln euros
|
RE
| |
05-06 |
Rovi expects risperidone to reach potential sales of 100-200 mln euros globally over next few years
|
RE
| |
05-06 |
Laboratorios Farmaceuticos Rovi S A : First three months of 2026 results press release
|
PU
| |
04-01 |
Rovi closes deal to buy pharmaceutical manufacturing facility in US
|
RE
| |
02-25 |
Laboratorios Farmaceuticos Rovi, S.A., 2025 Earnings Call, Feb 25, 2026
| | |
02-25 |
Pharmaceutical Company Rovi Increases Net Profit Thanks to Okedi and Heparin Sales
|
RE
| |
02-25 |
Drugmaker Rovi's net profit rises on higher Okedi, heparin sales
|
RE
| |
02-25 |
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2025
|
CI
| |
02-25 |
Laboratorios Farmaceuticos Rovi, S.A. Provides Earnings Guidance for the Fiscal Year 2026
|
CI
| |
02-25 |
ROVI Proposes Dividend Distribution for the Year 2025
|
CI
| |
02-25 |
Laboratorios Farmaceuticos Rovi S A : 2025 results press release
|
PU
| |
02-25 |
Rovi to propose dividend of 0.9594 eur/shr
|
RE
| |
02-25 |
Rovi FY Ebitda 216.2 mln euros
|
RE
| |
02-25 |
Rovi FY net profit at 140.4 mln euros
|
RE
| |
11-18 |
Rovi and Roche sign final agreement for manufacture of new medicine
|
RE
| |
11-18 |
Laboratorios Farmaceuticos Rovi S A : ROVI releases the press release in relation to the signing of the definitive collaboration agreement with Roche for the manufacture of a new medicine in development
|
PU
| |
11-06 |
Rovi sees 2026 operating revenue to increase by up to low double-digit percentage vs 2025
|
RE
|
No results match your criteria Select your edition All financial news and data tailored to specific country editions | 
